Head-to-Head drug battle to stop Crohn's patients needing surgery
NCT ID NCT07444060
Summary
This study aims to see which of two existing biologic drugs, guselkumab or ustekinumab, works better for people with Crohn's disease who have developed a narrowing (stricture) in their bowel. It will follow 100 adults for a year to see if the drug successfully controls their disease, improves their symptoms and quality of life, and most importantly, helps them avoid needing surgery or a procedure to widen the bowel.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IBD - INFLAMMATORY BOWEL DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Second Affiliated Hospital, School of Medicine, Zhejiang University
RECRUITINGHangzhou, Zhejiang, 310000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.